A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
Authors
Manegold, Cvan Zandwijk, N
Szczesna, A
Zatloukal, P
Au, J
Blasinska-Morawiec, M
Serwatowski, P
Krzakowski, M
Jassem, J
Tan, E
Benner, R
Ingrosso, A
Meech, S
Readett, D
Thatcher, Nick
Affiliation
Interdisciplinary Thoracic Oncology, Department of Surgery, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.Issue Date
2012-01
Metadata
Show full item recordAbstract
This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC).Citation
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. 2012, 23 (1):72-7 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdr030PubMed ID
21464154Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdr030